{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:45:22Z","timestamp":1792791922686,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T00:00:00Z","timestamp":1511740800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI13\/00557, PI13\/0636, PI1300393 and PI16\/153, PT13\/0010\/0005"],"award-info":[{"award-number":["PI13\/00557, PI13\/0636, PI1300393 and PI16\/153, PT13\/0010\/0005"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003030","name":"Ag\u00e8ncia de Gesti\u00f3 d\u2019Ajuts Universitaris i de Recerca","doi-asserted-by":"publisher","award":["SGR567"],"award-info":[{"award-number":["SGR567"]}],"id":[{"id":"10.13039\/501100003030","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Xarxa de Bancs de tumors","award":["Pla Director d'Oncologia de Catalunya"],"award-info":[{"award-number":["Pla Director d'Oncologia de Catalunya"]}]},{"DOI":"10.13039\/501100008782","name":"Sociedad Espa\u00f1ola de Hematolog\u00eda y Hemoterapia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008782","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008792","name":"Novartis Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008792","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1007\/s00277-017-3193-5","type":"journal-article","created":{"date-parts":[[2017,11,27]],"date-time":"2017-11-27T10:38:46Z","timestamp":1511779126000},"page":"443-451","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up"],"prefix":"10.1007","volume":"97","author":[{"given":"Alicia","family":"Sen\u00edn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Concepci\u00f3n","family":"Fern\u00e1ndez-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatriz","family":"Bellosillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Camacho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel","family":"Longar\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Angona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carles","family":"Besses","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-4619","authenticated-orcid":false,"given":"Alberto","family":"\u00c1lvarez-Larr\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,11,27]]},"reference":[{"issue":"9464","key":"3193_CR1","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","volume":"365","author":"EJ Baxter","year":"2005","unstructured":"Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S et al (2005) Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 365(9464):1054\u20131061. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(05)74230-6","journal-title":"Lancet"},{"issue":"17","key":"3193_CR2","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1056\/NEJMoa051113","volume":"352","author":"R Kralovics","year":"2005","unstructured":"Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, Tichelli A, Cazzola M, Skoda RC (2005) A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 352(17):1779\u20131790. \nhttps:\/\/doi.org\/10.1056\/NEJMoa051113","journal-title":"N Engl J Med"},{"issue":"11","key":"3193_CR3","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/j.exphem.2008.05.006","volume":"36","author":"AR Moliterno","year":"2008","unstructured":"Moliterno AR, Williams DM, Rogers O, Isaacs MA, Spivak JL (2008) Phenotypic variability within the JAK2 V617F-positive MPD: roles of progenitor cell and neutrophil allele burdens. Exp Hematol 36(11):1480\u20131486. \nhttps:\/\/doi.org\/10.1016\/j.exphem.2008.05.006","journal-title":"Exp Hematol"},{"issue":"9501","key":"3193_CR4","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/S0140-6736(05)67785-9","volume":"366","author":"PJ Campbell","year":"2005","unstructured":"Campbell PJ, Scott LM, Buck G, Wheatley K, East CL, Marsden JT, Duffy A, Boyd EM, Bench AJ, Scott MA, Vassiliou GS, Milligan DW, Smith SR, Erber WN, Bareford D, Wilkins BS, Reilly JT, Harrison CN, Green AR (2005) Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study. Lancet 366(9501):1945\u20131953. \nhttps:\/\/doi.org\/10.1016\/S0140-6736(05)67785-9","journal-title":"Lancet"},{"issue":"7","key":"3193_CR5","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1038\/leu.2008.113","volume":"22","author":"AM Vannucchi","year":"2008","unstructured":"Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A (2008) Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia 22(7):1299\u20131307. \nhttps:\/\/doi.org\/10.1038\/leu.2008.113","journal-title":"Leukemia"},{"issue":"5","key":"3193_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1111\/j.1365-2141.2009.07804.x","volume":"146","author":"A Alvarez-Larr\u00e1n","year":"2009","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Mart\u00ednez-Avil\u00e9s L, Saumell S, Salar A, Abella E, Gimeno E, Serrano S, Florensa L, S\u00e1nchez B, Pedro C, Besses C (2009) Postpolycythaemic myelofibrosis: frequency and risk factors for this complication in 116 patients. Br J Haematol 146(5):504\u2013509. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2009.07804.x","journal-title":"Br J Haematol"},{"issue":"9","key":"3193_CR7","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1038\/leu.2010.148","volume":"24","author":"F Passamonti","year":"2010","unstructured":"Passamonti F, Rumi E, Pietra D, Elena C, Boveri E, Arcaini L, Roncoroni E, Astori C, Merli M, Boggi S, Pascutto C, Lazzarino M, Cazzola M (2010) A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications. Leukemia 24(9):1574\u20131579. \nhttps:\/\/doi.org\/10.1038\/leu.2010.148","journal-title":"Leukemia"},{"issue":"5","key":"3193_CR8","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/ajh.23676","volume":"89","author":"A Alvarez-Larr\u00e1n","year":"2014","unstructured":"Alvarez-Larr\u00e1n A, Bellosillo B, Pereira A, Kerguelen A, Hern\u00e1ndez-Boluda JC, Mart\u00ednez-Avil\u00e9s L et al (2014) JAK2V617F monitoring in polycythemia vera and essential thrombocythemia: clinical usefulness for predicting myelofibrotic transformation and thrombotic events. Am J Hematol 89(5):517\u2013523. \nhttps:\/\/doi.org\/10.1002\/ajh.23676","journal-title":"Am J Hematol"},{"issue":"25","key":"3193_CR9","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","volume":"369","author":"J Nangalia","year":"2013","unstructured":"Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC, Avezov E, Li J, Kollmann K, Kent DG, Aziz A, Godfrey AL, Hinton J, Martincorena I, van Loo P, Jones AV, Guglielmelli P, Tarpey P, Harding HP, Fitzpatrick JD, Goudie CT, Ortmann CA, Loughran SJ, Raine K, Jones DR, Butler AP, Teague JW, O\u2019Meara S, McLaren S, Bianchi M, Silber Y, Dimitropoulou D, Bloxham D, Mudie L, Maddison M, Robinson B, Keohane C, Maclean C, Hill K, Orchard K, Tauro S, Du M-Q, Greaves M, Bowen D, Huntly BJP, Harrison CN, Cross NCP, Ron D, Vannucchi AM, Papaemmanuil E, Campbell PJ, Green AR (2013) Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 369(25):2391\u20132405. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1312542","journal-title":"N Engl J Med"},{"issue":"14","key":"3193_CR10","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220\u20132228. \nhttps:\/\/doi.org\/10.1182\/blood-2013-11-537167","journal-title":"Blood"},{"issue":"3","key":"3193_CR11","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/bjh.14269","volume":"175","author":"S Delic","year":"2016","unstructured":"Delic S, Rose D, Kern W, Nadarajah N, Haferlach C, Haferlach T, Meggendorfer M (2016) Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera. Br J Haematol 175(3):419\u2013426. \nhttps:\/\/doi.org\/10.1111\/bjh.14269","journal-title":"Br J Haematol"},{"issue":"1","key":"3193_CR12","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1182\/bloodadvances.2016000216","volume":"1","author":"A Tefferi","year":"2017","unstructured":"Tefferi A, Lasho T, Guglielmelli P, Finke CM, Rotunno G, Elala Y et al (2017) Targeted deep sequencing in polycythemia vera and essential thrombocythemia. Blood advances 1(1):21\u201330","journal-title":"Blood advances"},{"issue":"7","key":"3193_CR13","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2011-02-292102","volume":"118","author":"W Vainchenker","year":"2011","unstructured":"Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA (2011) New mutations and pathogenesis of myeloproliferative neoplasms. Blood 118(7):1723\u20131735. \nhttps:\/\/doi.org\/10.1182\/blood-2011-02-292102","journal-title":"Blood"},{"issue":"7","key":"3193_CR14","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa1412098","volume":"372","author":"CA Ortmann","year":"2015","unstructured":"Ortmann CA, Kent DG, Nangalia J, Silber Y, Wedge DC, Grinfeld J, Baxter EJ, Massie CE, Papaemmanuil E, Menon S, Godfrey AL, Dimitropoulou D, Guglielmelli P, Bellosillo B, Besses C, D\u00f6hner K, Harrison CN, Vassiliou GS, Vannucchi A, Campbell PJ, Green AR (2015) Effect of mutation order on myeloproliferative neoplasms. N Engl J Med 372(7):601\u2013612. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1412098","journal-title":"N Engl J Med"},{"issue":"4","key":"3193_CR15","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","volume":"108","author":"R Kralovics","year":"2006","unstructured":"Kralovics R, Teo SS, Li S, Theocharides A, Buser AS, Tichelli A, Skoda RC et al (2006) Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders. Blood 108(4):1377\u20131380. \nhttps:\/\/doi.org\/10.1182\/blood-2005-11-009605","journal-title":"Blood"},{"issue":"9","key":"3193_CR16","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1038\/leu.2013.119","volume":"27","author":"AM Vannucchi","year":"2013","unstructured":"Vannucchi AM, Lasho TL, Guglielmelli P, Biamonte F, Pardanani A, Pereira A, Finke C, Score J, Gangat N, Mannarelli C, Ketterling RP, Rotunno G, Knudson RA, Susini MC, Laborde RR, Spolverini A, Pancrazzi A, Pieri L, Manfredini R, Tagliafico E, Zini R, Jones A, Zoi K, Reiter A, Duncombe A, Pietra D, Rumi E, Cervantes F, Barosi G, Cazzola M, Cross NCP, Tefferi A (2013) Mutations and prognosis in primary myelofibrosis. Leukemia 27(9):1861\u20131869. \nhttps:\/\/doi.org\/10.1038\/leu.2013.119","journal-title":"Leukemia"},{"issue":"50","key":"3193_CR17","doi-asserted-by":"publisher","first-page":"E5401","DOI":"10.1073\/pnas.1407792111","volume":"111","author":"R Rampal","year":"2014","unstructured":"Rampal R, Ahn J, Abdel-Wahab O, Nahas M, Wang K, Lipson D, Otto GA, Yelensky R, Hricik T, McKenney AS, Chiosis G, Chung YR, Pandey S, van den Brink MRM, Armstrong SA, Dogan A, Intlekofer A, Manshouri T, Park CY, Verstovsek S, Rapaport F, Stephens PJ, Miller VA, Levine RL (2014) Genomic and functional analysis of leukemic transformation of myeloproliferative neoplasms. Proc Natl Acad Sci U S A 111(50):E5401\u2013E5410. \nhttps:\/\/doi.org\/10.1073\/pnas.1407792111","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"11","key":"3193_CR18","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.95","volume":"5","author":"S Cerquozzi","year":"2015","unstructured":"Cerquozzi S, Tefferi A (2015) Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors. Blood Cancer J 5(11):e366. \nhttps:\/\/doi.org\/10.1038\/bcj.2015.95","journal-title":"Blood Cancer J"},{"issue":"4","key":"3193_CR19","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092\u20131097. \nhttps:\/\/doi.org\/10.1182\/blood-2007-04-083501","journal-title":"Blood"},{"issue":"2","key":"3193_CR20","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/sj.leu.2404914","volume":"22","author":"G Barosi","year":"2008","unstructured":"Barosi G, Mesa RA, Thiele J, Cervantes F, Campbell PJ, Verstovsek S, Dupriez B, Levine RL, Passamonti F, Gotlib J, Reilly JT, Vannucchi AM, Hanson CA, Solberg LA, Orazi A, Tefferi A, International Working Group for Myelofibrosis Research and Treatment (IWG-MRT) (2008) Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment. Leukemia 22(2):437\u2013438. \nhttps:\/\/doi.org\/10.1038\/sj.leu.2404914","journal-title":"Leukemia"},{"issue":"6","key":"3193_CR21","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1111\/j.1365-2141.2009.08019.x","volume":"148","author":"G Barosi","year":"2010","unstructured":"Barosi G, Birgegard G, Finazzi G, Griesshammer M, Harrison C, Hasselbalch H, Kiladijan JJ, Lengfelder E, Mesa R, Mc Mullin MF, Passamonti F, Reilly JT, Vannucchi AM, Barbui T (2010) A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process. Br J Haematol 148(6):961\u2013963. \nhttps:\/\/doi.org\/10.1111\/j.1365-2141.2009.08019.x","journal-title":"Br J Haematol"},{"issue":"22","key":"3193_CR22","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","volume":"122","author":"E Papaemmanuil","year":"2013","unstructured":"Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, Yoon CJ, Ellis P, Wedge DC, Pellagatti A, Shlien A, Groves MJ, Forbes SA, Raine K, Hinton J, Mudie LJ, McLaren S, Hardy C, Latimer C, Della Porta MG, O\u2019Meara S, Ambaglio I, Galli A, Butler AP, Walldin G, Teague JW, Quek L, Sternberg A, Gambacorti-Passerini C, Cross NCP, Green AR, Boultwood J, Vyas P, Hellstrom-Lindberg E, Bowen D, Cazzola M, Stratton MR, Campbell PJ, on behalf of the Chronic Myeloid Disorders working group of the International Cancer Genome Consortium (2013) Clinical and biological implications of driver mutations in myelodysplastic syndromes. Blood 122(22):3616\u20133627. \nhttps:\/\/doi.org\/10.1182\/blood-2013-08-518886","journal-title":"Blood"},{"issue":"5","key":"3193_CR23","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJMc1012718","volume":"364","author":"A Harutyunyan","year":"2011","unstructured":"Harutyunyan A, Klampfl T, Cazzola M, Kralovics R (2011) p53 lesions in leukemic transformation. N Engl J Med 364(5):488\u2013490","journal-title":"N Engl J Med"},{"issue":"14","key":"3193_CR24","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","volume":"115","author":"PA Beer","year":"2010","unstructured":"Beer PA, Delhommeau F, LeCou\u00e9dic JP, Dawson MA, Chen E, Bareford D et al (2010) Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm. Blood 115(14):2891\u20132900. \nhttps:\/\/doi.org\/10.1182\/blood-2009-08-236596","journal-title":"Blood"},{"issue":"19","key":"3193_CR25","doi-asserted-by":"publisher","first-page":"4480","DOI":"10.1182\/blood-2011-11-390252","volume":"119","author":"SJ Zhang","year":"2012","unstructured":"Zhang SJ, Rampal R, Manshouri T, Patel J, Mensah N, Kayserian A, Hricik T, Heguy A, Hedvat C, Gonen M, Kantarjian H, Levine RL, Abdel-Wahab O, Verstovsek S (2012) Genetic analysis of patients with leukemic transformation of myeloproliferative neoplasms shows recurrent SRSF2 mutations that are associated with adverse outcome. Blood 119(19):4480\u20134485. \nhttps:\/\/doi.org\/10.1182\/blood-2011-11-390252","journal-title":"Blood"},{"issue":"4","key":"3193_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1056\/NEJMc0910063","volume":"362","author":"A Green","year":"2010","unstructured":"Green A, Beer P (2010) Somatic mutations of IDH1 and IDH2 in the leukemic transformation of myeloproliferative neoplasms. N Engl J Med 362(4):369\u2013370. \nhttps:\/\/doi.org\/10.1056\/NEJMc0910063","journal-title":"N Engl J Med"},{"issue":"5","key":"3193_CR27","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/bjh.14762","volume":"178","author":"A Alvarez-Larr\u00e1n","year":"2017","unstructured":"Alvarez-Larr\u00e1n A, Sen\u00edn A, Fern\u00e1ndez-Rodr\u00edguez C, Pereira A, Arellano-Rodrigo E, G\u00f3mez M, Ferrer-Marin F, Mart\u00ednez-L\u00f3pez J, Camacho L, Colomer D, Angona A, Navarro B, Cervantes F, Besses C, Bellosillo B, Hern\u00e1ndez-Boluda JC (2017) Impact of genotype on leukaemic transformation in polycythaemia vera and essential thrombocythaemia. Br J Haematol 178(5):764\u2013771. \nhttps:\/\/doi.org\/10.1111\/bjh.14762","journal-title":"Br J Haematol"},{"issue":"6","key":"3193_CR28","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1182\/blood-2011-10-387787","volume":"119","author":"A Alvarez-Larr\u00e1n","year":"2012","unstructured":"Alvarez-Larr\u00e1n A, Pereira A, Cervantes F, Arellano-Rodrigo E, Hern\u00e1ndez-Boluda JC, Ferrer-Mar\u00edn F et al (2012) Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera. Blood 119(6):1363\u20131369. \nhttps:\/\/doi.org\/10.1182\/blood-2011-10-387787","journal-title":"Blood"},{"key":"3193_CR29","doi-asserted-by":"publisher","unstructured":"Bartels S, Faisal M, B\u00fcsche G, Schlue J, Kreipe H, Lehmann U (2017) Fibrotic progression in polycythemia vera is associated with early concomitant driver-mutations besides JAK2. Leukemia. \nhttps:\/\/doi.org\/10.1038\/leu.2017.298","DOI":"10.1038\/leu.2017.298"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-017-3193-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-017-3193-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T22:33:27Z","timestamp":1517524407000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-017-3193-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,27]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["3193"],"URL":"https:\/\/doi.org\/10.1007\/s00277-017-3193-5","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732188943.793583129","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,11,27]]}}}